IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 51-75 out of 1136.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 > >>

Public Release: 23-Nov-2012
New test may improve cervical cancer detection
Routine smear tests have considerably reduced the number of cases of cervical cancer, but despite intensive screening 250 women in Sweden still die from the disease every year. Researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, have developed new methods of minimizing the number of missed cases and making diagnosis more reliable.

Contact: Maria Lidqvist
Maria.lidqvist@fdab.com
46-070-601-3883
University of Gothenburg

Public Release: 23-Nov-2012
Proceedings of the National Academy of Sciences
Researchers link new molecular culprit to breast cancer progression
Johns Hopkins researchers have uncovered a protein "partner" commonly used by breast cancer cells to unlock genes needed for spreading the disease around the body. A report on the discovery, published November 5 on the website of the Proceedings of the National Academy of Sciences, details how some tumors get the tools they need to metastasize.
NIH/National Heart, Lung, and Blood Institute

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 22-Nov-2012
Proceedings of the National Academy of Sciences
Newly discovered effects of vitamin D on cancer
A team of researchers at McGill University have discovered a molecular basis for the potential cancer preventive effects of vitamin D.
Canadian Institutes of Health Research, National Cancer Institute, Canadian Cancer Society Research Institute

Contact: Cynthia Lee
cynthia.lee@mcgill.ca
514-398-6754
McGill University

Public Release: 21-Nov-2012
Cell
Drug resistance biomarker could improve cancer treatment
Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published by Cell Press November 21st in the journal Cell. The study reveals a biomarker that can predict responses to cancer drugs and offers a strategy to treat drug-resistant tumors based on their genetic signature.

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Public Release: 21-Nov-2012
Nature Cell Biology
A*STAR scientists identify potential drug target for inflammatory diseases including cancers
A*STAR scientists have identified the enzyme, telomerase, as a cause of chronic inflammation in human cancers. Chronic inflammation is now recognized as a key underlying cause for the development of many human cancers, autoimmune disorders, neurodegenerative diseases, and metabolic diseases such as diabetes. This enzyme, which is known to be responsible for providing cancer cells the endless ability to divide, is now found to also jumpstart and maintain chronic inflammation in cancers.
A*STAR

Contact: Vithya Selvam
vithya_selvam@a-star.edu.sg
656-826-6291
Agency for Science, Technology and Research (A*STAR), Singapore

Public Release: 21-Nov-2012
PLOS ONE
MicroRNA makes triple-negative breast cancer homesick
Carcinoma cells are epithelial cells gone bad and have learned to act like neurons, inappropriately activating TrkB signaling to escape the programmed cell death known as anoikis. They do it by a mutation that nixes production of a microRNA called miR-200c. When researchers at the University of Colorado Cancer Center reintroduced miR-200c to aggressive, triple-negative breast cancer cells, these cells regained sensitivity to anoikis and self-destructed.
National Institutes of Health, US Department of Defense

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 21-Nov-2012
Cancer Research
Kidney tumors have a mind of their own
New research has found there are several different ways that kidney tumors can achieve the same result -- namely, grow.

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital

Public Release: 21-Nov-2012
Cancer Discovery
MicroRNAs can convert normal cells into cancer promoters
Ovarian cancer cells use three microRNAs to convert normal, healthy cells into cancer-associated fibroblasts. These cells pump out chemical signals that help cancer cells multiply, invade healthy tissues and travel to distant sites.
Ovarian Cancer Research Fund

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center

Public Release: 21-Nov-2012
Cancer Discovery
Novel mechanism through which normal stromal cells become cancer-promoting cells identified
Change in three microRNAs' expression converted normal fibroblasts to cancer-associated fibroblasts. Restoring the pattern of microRNA expression reduced cancer-promoting qualities. Cytokines regulated by these specific microRNAs represent potential new targets for ovarian cancer treatment.

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 21-Nov-2012
Cell Reports
Stem cells develop best in 3-D
Scientists from the Danish Stem Cell Center at the University of Copenhagen are contributing important knowledge about how stem cells develop best into insulin-producing cells. In the long term this new knowledge can improve diabetes treatment with cell therapy. The results have just been published in the scientific journal Cell Reports.

Contact: Anne Grapin-Botton
anne.grapin-botton@sund.ku.dk
(45) 29-63-43-98
University of Copenhagen

Public Release: 21-Nov-2012
Lancet
New drug overcomes resistance in patients with rare sarcoma
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
Bayer HealthCare Pharmaceuticals, Dana-Farber/Harvard Cancer Center

Contact: Robbin Ray
robbin_ray@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 21-Nov-2012
Journal of Clinical Investigation
Pathway identified in human lymphoma points way to new blood cancer treatments
Research, shows for the first time that the "unfolded protein response" is active in patients with human lymphomas and mice genetically bred to develop lymphomas. Importantly, when the UPR is inactivated, lymphoma cells readily undergo cell death.
NIH/National Cancer Institute, Leukemia and Lymphoma Society Scholar, America Cancer Society

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 21-Nov-2012
Nature
Gateway enzyme for chemicals from catnip to cancer drug
Scientists have discovered an enzyme used in nature to make powerful chemicals from catnip to a cancer drug, vinblastine. The discovery opens up the prospect of producing these chemicals cheaply and efficiently.
Biotechnology and Biological Sciences Research Council

Contact: Zoe Dunford
zoe.dunford@nbi.ac.uk
44-016-032-55111
Norwich BioScience Institutes

Public Release: 21-Nov-2012
Structure
It takes two to tangle: Wistar scientists further unravel telomere biology
Wistar researchers have resolved the structure of that allows a telomere-related protein, Cdc13, to form dimers in yeast. Mutations in this region of Cdc13 put the kibosh on the ability of telomerase and other proteins to maintain telomeres.
Pennsylvania Department of Health, V Foundation, Emerald Foundation, NIH/National Institute of Aging

Contact: Greg Lester
glester@wistar.org
215-898-3934
The Wistar Institute

Public Release: 20-Nov-2012
Radiology
Novel breast screening technology increases diagnostic accuracy
The addition of three-dimensional breast imaging--a technology called tomosynthesis--to standard digital mammography significantly increases radiologists' diagnostic accuracy while reducing false positive recall rates, according to the results of a multi-center study.

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America

Public Release: 20-Nov-2012
Nano Letters
UAlberta prostate cancer researcher and team developing 'homing beacon drugs' to target cancer cells
A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.
Canadian Institutes of Health Research, Ontario Institute for Cancer Research

Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry

Public Release: 20-Nov-2012
New England Journal of Medicine
JTCC researchers play important role in groundbreaking study that may change transplant practices
Researchers from John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study published in the New England Journal of Medicine on Oct. 18 that may change the current blood and marrow transplantation practices. The phase III, multicenter study compared harvesting stem cells from bone marrow rather than blood and suggests there are benefits to both approaches, but no survival differences between the two methods.

Contact: Amy Leahing
aleahing@p4strategy.com
646-756-2694
John Theurer Cancer Center

Public Release: 20-Nov-2012
Macromolecular Bioscience
New electrically-conductive polymer nanoparticles can generate heat to kill colorectal cancer cells
Researchers at Wake Forest Baptist Medical Center have modified electrically-conductive polymers, commonly used in solar energy applications, to develop revolutionary polymer nanoparticles for a medical application. When the nanoparticles are exposed to infrared light, they generate heat that can be used to kill colorectal cancer cells.

Contact: Paula Faria
pfaria@wakehealth.edu
336-716-1279
Wake Forest Baptist Medical Center

Public Release: 19-Nov-2012
Genes and Development
Fruit fly studies guide investigators to misregulated mechanism in human cancers
Changes in how DNA interacts with histones -- the proteins that package DNA -- regulate many fundamental cell activities from stem cells maturing into a specific body cell type or blood cells becoming leukemic. These interactions are governed by a biochemical tug of war between repressors and activators, which chemically modify histones signaling them to clamp down tighter on DNA or move aside and allow a gene to be expressed.
National Institutes of Health, Stowers Institute, Jane Coffin Childs Memorial Fund for Medical Research

Contact: Gina Kirchweger
gxk@stowers.org
816-806-1036
Stowers Institute for Medical Research

Public Release: 19-Nov-2012
Personality and Social Psychology Bulletin
The benefits of gratitude, how weight stigma affects health, and more
Story leads and experts on the benefits of gratitude, the link between group victimhood and trust, how weight stigma affects health, and more, available online...

Contact: Lisa M.P. Munoz
spsp.publicaffairs@gmail.com
703-951-3195
Society for Personality and Social Psychology

Public Release: 19-Nov-2012
TGen, Scottsdale Healthcare lead worldwide study of new drug for patients with pancreatic cancer
A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the Translational Genomics Research Institute.

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 19-Nov-2012
Medical Physics
New tumor tracking technique may improve outcomes for lung cancer patients
Thomas Jefferson University researchers have shown that a real-time tracking technique can better predict and track tumor motion and deliver higher levels of radiation to lung cancer patients and others with moving tumor targets, and also successfully be implemented into existing clinical equipment.
National Institutes of Health

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 19-Nov-2012
Molecular and Cellular Biology
Some cells don't know when to stop
Certain mutated cells keep trying to replicate their DNA -- with disastrous results -- even after medications rob them of the raw materials to do so, according to new research from USC.
NIH/National Institute of General Medical Sciences

Contact: Robert Perkins
perkinsr@usc.edu
213-740-9226
University of Southern California

Public Release: 19-Nov-2012
Journal of Pediatrics
Smoking in pregnancy tied to lower reading scores
Yale School of Medicine researchers have found that children born to mothers who smoked more than one pack per day during pregnancy struggled on tests designed to measure how accurately a child reads aloud and comprehends what they read.
National Institutes of Health, UK Medical Research Council, Wellcome Trust, University of Bristol

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University

Public Release: 19-Nov-2012
American Journal of Epidemiology
Can't stop? Smoking less helps
Vicki Myers of Tel Aviv University found that while quitters had the biggest improvements in mortality rates, even those who reduced their smoking were able to cut their mortality risk by 15 percent. These results show that smoking less is a valid risk reduction strategy.

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University

Showing releases 51-75 out of 1136.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 > >>

  Search News Releases

     

 

 

EurekAlert!